Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | APAF1 | O14727 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5999780 | 0.85 | MAPT (0.52) | MAPTLMNARAB9AKDM4EALDH1A1 | |
| SCHEMBL6001534 | 0.84 | MAPK14 (0.48) | MAPTTDP1LMNAKDM4EHPGD | |
| SCHEMBL6001053 | 0.83 | DYRK1A (0.47) | MAPTLMNARAB9AHPGDKMT2A | |
| SCHEMBL6001745 | 0.78 | BCL2 (0.45) | MAPTTDP1LMNAKDM4EHPGD | |
| SCHEMBL6001482 | 0.78 | ERO1A (0.47) | MAPTTDP1LMNARAB9AALDH1A1 | |
| SCHEMBL6000950 | 0.75 | STAT3 (0.46) | MAPTLMNARAB9AKDM4EHPGD | |
| SCHEMBL20187694 | 0.75 | MEN1 (0.43) | MAPTLMNARAB9AKDM4EHPGD | |
| SCHEMBL16904665 | 0.73 | CNR1 (0.50) | MAPTTDP1LMNAKDM4EHPGD | |
| SCHEMBL20187666 | 0.72 | HPGD (0.51) | MAPTTDP1LMNARAB9AKDM4E | |
| SCHEMBL23041058 | 0.72 | PDGFRB (0.62) | MAPTTDP1LMNARAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10851075-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190263768-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. | 2019-08-29 | — | — | US | disclosed |
| EP-3058941-B1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2019-05-22 | — | — | EP | disclosed |
| US-9834532-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834532-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170197932-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170197932-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2017-07-13 | — | — | US | disclosed |
| EP-3058941-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | Boston Biomedical, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-2194987-B1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-8877803-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877803-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | BOSTON BIOMEDICAL, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20110112180-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| US-20110112180-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2009036059-A2 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | BOSTON BIOMEDICAL, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20060142271-A1 | Novel lapacho compounds and methods of use thereof | MUNSTER, UNIVERSITY OF (DE) | 2006-06-29 | — | — | US | disclosed |
| EP-1551392-A2 | NOVEL LAPACHO COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004026253-A2 | NOVEL LAPACHO COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142271-A1 | Novel lapacho compounds and methods of use thereof | XIAP, PIN1, NQO1 | MAPT 3494/4885TDP1 3541/4885LMNA 34/4885 |
| US-20110112180-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, STAT5B | MAPT 4328/4885TDP1 3933/4885LMNA 4157/4885 |
| US-20170197932-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, JAK2 | MAPT 4275/4885TDP1 3958/4885LMNA 4062/4885 |
| US-10851075-B2 | Stat3 pathway inhibitors and cancer stem cell inhibitors | STAT3, STAT1, JAK2 | MAPT 4350/4885TDP1 3940/4885LMNA 4110/4885 |
| US-20190263768-A1 | NOVEL STAT3 PATHWAY INHIBITORS AND CANCER STEM CELL INHIBITORS | STAT3, STAT1, STAT5B | MAPT 4328/4885TDP1 3933/4885LMNA 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.